Translate this page into:
Detection of AmpC β-lactamases production in Acinetobacter species by inhibitor (disk) based & modified three dimensional (enzyme extraction) methods
† For correspondence: profdvrsaigopal@rediffmail.com
This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
This article was originally published by Medknow Publications & Media Pvt Ltd and was migrated to Scientific Scholar after the change of Publisher.
Sir,
Among the nosocomial infections caused by Gram- negative bacteria, the Acinetobacter spp. is one of the established1 and predictable opportunistic pathogens in immunocompromised patients23. AmpC β-lactamases are class C or group I cephalosporinases and non susceptible to alpha methoxy β-lactams such as cefoxitin or cefotetan. The detection of these β-lactamases is clinically significant because these confer resistance to narrow, extended and broad spectrum cephalosporins as well as β-lactam/β-lactamase inhibitor combinations4. This study was undertaken to detect the presence of AmpC β-lactamase in clinical isolates of Acinetobacter species by two phenotypic methods.
A total number of 136 non repetitive cefoxitin resistant clinical isolates of Acinetobacter spp. were obtained during January to December 2012 in the microbiology laboratory, Sri Venkateswara Institute of Medical Sciences, Tirupati, Andhra Pradesh, India. The isolates were identified only to the Genus level and speciation was not done. The zone size <18 mm around the cefoxitin disc was used as a screening test for the presence of AmpC β-lactamase production5.
All cefoxitin resistant isolates were studied for the presence of AmpC enzyme by the modified three dimensional method5. In this method three kinds of results were recorded. Isolates that showed clear distortion of zone of inhibition of cefoxitin were considered as strong AmpC producers. Isolates with no distortion were considered AmpC non producers and isolates with little distortion were considered as weak or intermediate AmpC producer.
The inhibitor (disc) based disc method6 was performed to confirm the AmpC producers. The test culture was swabbed on Mueller-Hinton agar (Hi-media, Mumbai) plates and cefoxitin (30 μg) and cefoxitin/boronic acid (30/400 μg) discs were placed at a distance of 20 mm from centre to centre. An increase of >0.5 mm around cefoxitin/boronic acid compared to cefoxitin alone was considered positive for the presence of AmpC production6.
Among the 136 isolates screened, 82 (60.29%) were positive for the AmpC β-lactamase production by the inhibitor (disc) method. Of the total 136 isolates, 84 (61.76%) were strong AmpC producers, 16 (11.76%) intermediate or weak AmpC producers, and 36 (26.47%) were negative for the AmpC producers by the modified three dimensional (enzyme extract) method.
The isolates harbouring AmpC β-lactamases are shown to be largely restricted to the hospitalized patients only578. The CLSI (Clinical and Laboratory Standards Institute) guidelines9 do not indicate the screening and confirmatory tests for detecting AmpC β-lactamases in Acinetobacter species. The modified three dimensional5 test is a confirmatory test for detecting both inducible and non inducible AmpC β-lactamases but is technically demanding. In case of inhibitor method using boronic acid with cefoxitin is simple, and this test is sensitive to detect the plasmid mediated AmpC β-lactamases1011 as well as similar to the ESBL confirmatory test5. Among the cefoxitin resistant Gram-negative isolates, Sasirekha12 reported 20.4 per cent positive for AmpC production whereas Manoharan et al13 reported 36.5 per cent positivity. In a study form Kolkata, 32.77 per cent of isolates were reported positive for ampC by Amp disk test14. Several other studies have also reported AmpC β-lactamase positive Acinetobacter spp.14151617.
In this study, 84 (61.76%) and 82 (60.29%) isolates were determined as AmpC producers by modified three dimensional and boronic acid inhibitor methods, respectively. When the two phenotypic methods were compared, the inhibitor method failed to detect the presence of AmpC in only two isolates; 38.23 per cent of cefoxitin resistant isolates were negative for AmpC production by both methods. The resistance to cefoxitin can also be mediated by certain class A beta lactamses, carbapenemases and decreased production of outer membrane porins18. In a study from Turkey, more positives (89.76%) were observed by three dimensional method than by boronic acid disk test (85.03%)19. However, Bakthavatchalu et al20 reported higher percentage of positives (93%) of AmpC producers by boronic acid inhibitor test than by the three dimensional method (91%). Lee et al21 compared modified Hodge test with boronic acid test and EDTA disk test to evaluate the presence of AmpC beta lactamase and reported the combination-disk test with boronic acid as a sensitive and efficient test for detecting AmpC producers.
In conclusion, our findings suggest that the inhibitor based disc method can be used in routine clinical microbiology laboratories to confirm the presence of AmpC in Acinetobacter species.
References
- Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008;21:538-82.
- [Google Scholar]
- Acinetobacter spp. as nosocomial pathogens: microbiological, clinical, and epidemiological features. Clin Microbiol Rev. 1996;9:148-65.
- [Google Scholar]
- History and importance of Acinetobacter species: role in infections, treatment and cost implications. In: Bergogne-Berezin E, Marie Laure, Joly-Guillou, Kevin J, Towner, eds. Acinetobacter: microbiology, epidemiology, infections, management. New York, USA: CRC Press; 1996. p. :1-12.
- [Google Scholar]
- A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother. 1995;39:1211-33.
- [Google Scholar]
- Occurrence and detection of AmpC b-lactamases among Gram negative clinical isolates using a modified three-dimensional test at Guru Tegh Bahadur Hospital, Delhi, India. J Antimicrob Chemother. 2003;51:415-8.
- [Google Scholar]
- Coudron. Inhibitor-based methods for detection of plasmid-mediated AmpC β-lactamases in Klebsiella spp., Escherichia coli and Proteus mirabilis. J Clin Microbiol. 2005;43:4163-7.
- [Google Scholar]
- Multi drug resistant Pseudomonas aeruginosa strains harbouring R-plasmids and AmpC β-lactamase isolated from hospitalized burn patients in a tertiary care hospital of north India. FEMS Microbiol Lett. 2003;228:181-6.
- [Google Scholar]
- AmpC β-lactamase producing bacterial isolates from Kolkata hospital. Indian J Med Res. 2005;122:224-33.
- [Google Scholar]
- Clinical Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: Twenty second informational supplements. M100-S22. Wayne, PA, USA: CLSI; 2012.
- [Google Scholar]
- Detection of plasmid-mediated class C β-lactamases. Int J Infect Dis. 2007;11:191-7.
- [Google Scholar]
- Use of boronic acid disc methods to detect the combined expression of plasmid-mediated AmpC β-lactamases and extended-spectrum β-lactamases in clinical isolates of Klebsiella spp., Salmonella spp., and Proteus mirabilis. Diagn Microbiol Infect Dis. 2007;57:315-8.
- [Google Scholar]
- Prevalence of ESBL, AmpC β-lactamases and MRSA among uropathogens and its antibiogram. Expclinsciintl. 2013;12:81-8.
- [Google Scholar]
- Phenotypic & molecular characterization of AmpC β-lactamases among Escherichia coli, Klebsiella spp. & Enterobacter spp. from five Indian Medical Centers. Indian J Med Res. 2012;135:359-64.
- [Google Scholar]
- Surveillance on extended spectrum β-lactamase and AmpC β-lactamase producing gram negative isolates from nosocomial infections. Arch clin microbiol. 2012;3:1-7.
- [Google Scholar]
- AmpC beta lactamases among Gram negative clinical isolates from a tertiary hospital, South India. Braz j Microbiol. 2010;41:596-602.
- [Google Scholar]
- Prevalence of extended spectrum beta lactamases, AmpC beta lactamase and metallo beta lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii in an intensive care unit in a tertiary care hospital. J Sci Soc. 2013;40:28-31.
- [Google Scholar]
- Molecular description of plasmid-mediated AmpC β-lactamases among nosocomial isolates of Escherichia coli & Klebsiella pneumoniae from six different hospitals in India. Indian J Med Res. 2012;135:114-9.
- [Google Scholar]
- Detection of plasmid mediated AmpC β-lactamase in Escherichia coli and Klebsiella pneumoniae. Indian J Med Microbiol. 2013;31:53-9.
- [Google Scholar]
- Detection of ESBL among AmpC producing Enterobactriaceae using inhibitor based method. Pan Afr Med J. 2013;14:28.
- [Google Scholar]
- Comparison of 3 phenotypic-detection methods for identifying plasmid-mediated AmpC beta-lactamase-producing Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis strains. Korean J Lab Med. 2004;29:448-54.
- [Google Scholar]
